Biotech company Moderna, co-founded by HSCI scientist Derrick Rossi, is set to bring a new class of treatments to patients.

Summary

• Derrick Rossi’s research into using mRNA as a new kind of therapeutic was initially supported by HSCI seed funding, and gave rise to biotech company Moderna Therapeutics.
• Moderna’s public offering of $600 million is the largest ever of a venture-capital-backed biotechnology company, reflecting the potential of its new technology: mRNA therapeutics
• Moderna’s success in creating therapies that will benefit patients reflects the crucial role of HSCI in enabling early-stage, high-risk research.

... Read more about HSCI-supported research leads to new class of therapeutics

Mario Suva and Ramesh Shivdasani are tackling some of the toughest, meanest cancers to clear a path to better treatments.

• Suva and Shivdasani are using every approach in their arsenal to figure out what makes cancer cells arise from healthy tissue.
• Armed with enough new knowledge about how cancer arises, they want to take truer aim at cancer cells, the cancer cell lineage, and factors that make cells go awry.
• Their new approach to cancer management would combine gene and cell therapies to kill the cancer...

HSCI scientists identify a potential target for treating neuropathic pain

Engineered cancer cells can deliver therapeutic molecules to tumors in mice